N/A N=484

Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)

Allogeneic Stem Cell Transplant · Graft Versus Host Disease · Hematologic Malignancy · Stem Cell Transplant Complications

Bottom Line

View on ClinicalTrials.gov: NCT03419078 ↗

Enrolled (actual)

484

Serious AEs

0.0%

Results posted

Oct 2019

Primary outcome: Primary: Number of Participants With Acute Graft Versus Host Disease (GvHD) at Any Site (Grade II or Above) and Acute GvHD of the Gut of Any Grade — 75; 73; 31; 63 Participants

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Pediatric, Adult, Older Adult · 17+ yrs
Sex: All
Sponsor: Imperial College Healthcare NHS Trust
Primary completion: Jun 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Acute Graft Versus Host Disease (GvHD) at Any Site (Grade II or Above) and Acute GvHD of the Gut of Any Grade	75; 73; 31; 63; 63; 27	—
PRIMARY Non Relapse Mortality	8.2; 17.6; 27.5	—
SECONDARY Graft Versus Host Disease-free and Relapse-free Survival	39.183; 29.729; 27.472	—
SECONDARY 5 Year Survival	53.877; 45.946; 41.758	—

Summary

Retrospective case-note review to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation.

Eligibility Criteria

Inclusion Criteria

Patients undergoing their first HCT for a hematologic malignancy
Undergoing HCT using a sibling or unrelated donor
Undergoing HCT infusion between January 2000 and December 2014

Exclusion Criteria

HCT using umbilical cord blood donors
HCT using haploidentical donors

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03419078). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.